Taikang Life and Lilly Asia Ventures, which backed the initial $59.7m series B round last year, have also contributed to a $35m series B+ round of Hangzhou Just Biotherapeutics.
China-based biotherapeutics developer Hangzhou Just Biotherapeutics (HJB) closed a $35m series B+ round yesterday backed by insurance provider Taikang Life and Lilly Asia Ventures, the investment unit of pharmaceutical firm Eli Lilly.
Hillhouse Capital led the series B+ round, which also included Arch Venture Partners, BOCGI Zheshang Capital and Singapore state-owned investment firm Temasek.
HJB was founded by Just Biotherapeutics, a US-based biotherapeutics technology developer, in 2016. It focuses on areas including oncology, genetic rare diseases and metabolic disorders.
The…
